Physician profile
Firas Akhrass
NPI 1487636205
$801,494.62
in general payments reported to CMS, 2019-2025
70 companies · $184K in 2025
The $184K reported for 2025 was more than what 99% of Endocrinology, Diabetes & Metabolism providers received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $134K · 2020: $76K · 2022: $158K · 2023: $116K · 2024: $134K · 2025: $184K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $288K · Honoraria: $60K · Food and Beverage: $33K · Travel and Lodging: $30K · Consulting Fee: $23K · Education: $94.92.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $288,240.75 |
| Honoraria | $60,091.00 |
| Food and Beverage | $33,025.60 |
| Travel and Lodging | $30,153.48 |
| Consulting Fee | $22,635.00 |
| Education | $94.92 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $255,543.22 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Corcept Therapeutics | $120,741.80 | 2019-2025 | Korlym |
| Novo Nordisk INC | $118,865.19 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Madrigal Pharmaceuticals | $58,856.47 | 2024-2025 | Rezdiffra, Resmetirom |
| Xeris Pharmaceuticals, INC. | $44,234.83 | 2020-2025 | Recorlev, Gvoke Hypopen |
| Mannkind Corporation | $43,478.80 | 2019-2025 | Afrezza |
| Astrazeneca Pharmaceuticals Lp | $34,517.75 | 2019-2024 | Farxiga, Lokelma |
| Amgen INC. | $25,971.37 | 2019-2025 | Repatha, Evenity, Prolia |
| Boehringer Ingelheim Pharmaceuticals, INC. | $19,087.81 | 2019-2025 | Jardiance, Synjardy, Tradjenta |
| Janssen Pharmaceuticals, INC | $14,261.74 | 2019-2020 | |
| Amarin Pharma, INC. | $12,569.76 | 2019-2022 | |
| Cequr Corporation | $11,382.11 | 2022-2025 | Cequr Simplicity |
| Tandem Diabetes Care, INC. | $8,154.11 | 2019-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Esperion Therapeutics, INC. | $6,627.78 | 2020-2024 | Nexletol |
| Dexcom, INC. | $4,783.67 | 2019-2025 | Dexcom G6 Transmitter |
Show all 69 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $3,914.41 | 2022-2025 | |
| Merck Sharp & Dohme LLC | $2,395.31 | 2019-2022 | |
| Medtronic, INC. | $1,528.71 | 2022-2025 | Minimed 780g, Inpen Smart Insulin Delivery System, Intellis Adaptivestim |
| Abbott Laboratories | $1,499.25 | 2019-2025 | Freestyle Libre 3 |
| Sanofi-Aventis U.S. LLC | $1,430.19 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $1,400.44 | 2022-2025 | |
| Radius Health, INC. | $1,388.90 | 2019-2025 | Tymlos |
| Ascensia Diabetes Care US INC. | $1,340.27 | 2023-2025 | |
| Sequel Med Tech, LLC | $1,060.23 | 2024-2025 | Twiist |
| Abbvie INC. | $848.71 | 2019-2025 | Synthroid, Ubrelvy |
| Beta Bionics, INC. | $749.88 | 2023-2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Inset, Ilet Insulin Infusion Kit Contact Detach |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $538.34 | 2022-2024 | Cycloset |
| Antares Pharma, INC. | $516.78 | 2019-2023 | Xyosted, Tlando, Nocdurna |
| Allergan, INC. | $458.68 | 2019-2020 | |
| Medtronic Minimed, INC. | $409.08 | 2019-2020 | |
| Kyowa Kirin, INC. | $361.04 | 2023-2025 | Crysvita |
| Valeritas, INC. | $300.12 | 2019 | |
| Insulet Corporation | $283.61 | 2019-2025 | Omnipod |
| Opko Pharmaceuticals, LLC | $195.21 | 2019-2020 | |
| Companion Medical, INC. | $171.11 | 2019-2020 | |
| Recordati_rare_diseases_inc. | $150.53 | 2022-2025 | Isturisa, Signifor Lar |
| Regeneron Healthcare Solutions, INC. | $134.40 | 2022-2023 | Praluent, Evkeeza |
| Ultragenyx Pharmaceutical INC. | $114.45 | 2020-2022 | |
| Zealand Pharma US, INC. | $110.99 | 2020-2022 | |
| Becton, Dickinson and Company | $83.05 | 2019-2022 | |
| Soleno Therapeutics, INC. | $79.21 | 2025 | Vykat Xr |
| Tolmar, INC. | $65.76 | 2023-2024 | |
| Pfizer INC. | $60.93 | 2024-2025 | |
| Alexion Pharmaceuticals, INC. | $57.87 | 2023-2025 | Strensiq |
| Acerus Pharmaceuticals Corporation | $56.53 | 2020-2022 | |
| Vivus LLC | $56.24 | 2019-2022 | |
| Organogenesis INC. | $55.38 | 2023 | Puraply |
| Amphastar Pharmaceuticals, INC. | $54.89 | 2024-2025 | |
| Neurocrine Biosciences, INC. | $48.30 | 2025 | |
| Nalpropion Pharmaceuticals LLC | $47.70 | 2019 | |
| Bigfoot Biomedical INC | $42.10 | 2022 | |
| Ibsa Pharma INC. | $38.43 | 2020 | |
| Lifescan, INC. | $36.82 | 2020-2022 | |
| Averitas Pharma INC. | $33.97 | 2025 | Qutenza |
| Rhythm Pharmaceuticals, INC. | $32.30 | 2025 | Imcivree |
| Kvk-Tech, INC. | $26.50 | 2019 | |
| Almatica Pharma LLC | $24.25 | 2024 | Teriparatide |
| Roche Diabetes Care, INC. | $24.03 | 2019 | |
| Chiesi USA, INC. | $21.52 | 2024 | Mycapssa |
| Glaxosmithkline, LLC. | $20.84 | 2025 | Arexvy, Shingrix |
| Grt US Holding, INC. | $20.38 | 2022 | |
| Ascendis Pharma Endocrinology INC | $19.99 | 2025 | Yorvipath |
| Nestle Healthcare Nutrition INC. | $18.62 | 2020 | |
| Halozyme INC | $18.08 | 2023 | |
| Shire North American Group INC | $17.74 | 2019 | |
| Eusa Pharma (US) LLC | $17.71 | 2022 | |
| Horizon Therapeutics Plc | $16.64 | 2020 | |
| Ipsen Biopharmaceuticals, INC | $13.56 | 2022 | |
| Echosens North America, INC. | $8.23 | 2022 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Firas Akhrass listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.